$BMY Headlines Coach slides on downgrade; FuelCell

New Post Public Reply Private Reply Replies (0) Message Board

Jun 6, 2014 at 11:55 AM

$BMY Headlines

Coach slides on downgrade; FuelCell slumps on results 3:43 p.m. June 4, 2014 - Sue Chang
Rising health-care costs are enough to make you sick 6:00 a.m. May 29, 2014 - Al Lewis
Cisco jumps on profit beat; Plug Power gains on upgrade 3:35 p.m. May 15, 2014 - Sue Chang
Pfizer’s AstraZeneca bid is a ‘deal from hell’ 10:18 a.m. May 15, 2014 - Howard Gold
Bristol-Myers slides 4.7%, worst S&P 500 loser 9:33 a.m. May 15, 2014 - Sue Chang
Earnings roundup: Cubist, Merck gain as HCA, Bristol-Myers slide 11:48 a.m. April 29, 2014 - Russ Britt
Value trumps growth as investors pick Exxon over Tesla 10:48 a.m. April 29, 2014 - William L. Watts
Twitter, eBay, Sprint, Herbalife are stocks to watch 5:31 a.m. April 29, 2014 - Sue Chang
Market leaders energy, utilities face earnings gauntlet 11:17 a.m. April 28, 2014 - Wallace Witkowski
The market in a minute: Sell calls and puts 11:11 a.m. April 28, 2014 - The Trading Deck
GlaxoSmithKline exits cancer drugs 8:36 a.m. April 22, 2014 - MarketWatch.com
Merck: Hepatitis C drug has 98% cure rate in trial 11:43 a.m. April 10, 2014 - MarketWatch.com
Market rookie Five Prime's shares surge on deal with Bristol-Myers 12:01 p.m. March 17, 2014 - Russ Britt
RadioShack sinks; J.C. Penney gains on S&P outlook hike 5:19 p.m. March 4, 2014 - Sue Chang
Bristol-Myers plans late-stage tests on Yervoy as lung-cancer treatment 5:01 p.m. March 4, 2014 - Russ Britt
Billionaire Stan Druckenmiller's recent moves 12:50 p.m. Feb. 24, 2014 - Insider Monkey
Feds, pharma rivals team up on Alzheimer's 3:32 p.m. Feb. 6, 2014 - Elizabeth O'Brien
Merck hits a new high as analyst sees opening for new cancer drug 12:16 p.m. Jan. 27, 2014 - Russ Britt
U.S. stocks tumble; Dow drops 318 points 6:29 p.m. Jan. 24, 2014 - Anora Mahmudova
Juniper buoyed by Jana stake; Herbalife loss grows 4:50 p.m. Jan. 24, 2014 - Sue Chang

Top Analyst Upgrades and Downgrades: Apple, Lululemon, Microsoft, NBG, Twitter, Whole Foods and More 7:37 a.m. June 5, 2014 - 247WallSt.com
ASCO Meeting Day 4: Risks And Rewards Of Immunotherapy 1:08 p.m. June 4, 2014 - benzinga.com
ASCO Meeting Day 3: Do More Treatments Equal A Longer Life? 12:58 p.m. June 4, 2014 - benzinga.com
Bristol-Myers Squibb (BMY) Hosts Bristol-Myers Squibb Investor Event: ASCO 2014 (Transcript) 4:56 p.m. June 2, 2014 - Seeking Alpha
Incyte's 'IDO' Cancer Immunotherapy Causes Investor Scrum at ASCO '14 3:20 p.m. June 2, 2014 - TheStreet.com
Bristol Defends Data; Roche Shines In Cancer Showdown 1:14 p.m. June 2, 2014 - Investors Business Daily
3 Stocks Pushing The Drugs Industry Downward 1:03 p.m. June 2, 2014 - TheStreet.com
Drug Giants Advance Cancer Treatments 10:30 a.m. June 2, 2014 - FOXBusiness
Immunotherapies dominate the agenda at ASCO 8:01 a.m. June 2, 2014 - Seeking Alpha
Bristol's Immunotherapy Duo Doubles Survival in Melanoma Patients 7:33 a.m. June 2, 2014 - TheStreet.com
Merck Immunotherapy Posts Striking Results Against Advanced Melanoma 7:31 a.m. June 2, 2014 - TheStreet.com
Stock Futures Tick Up on China Data 7:31 a.m. June 2, 2014 - FOXBusiness
S&P 500 Crawls to New High Ahead of ISM Data 7:31 a.m. June 2, 2014 - FOXBusiness
Cancer Drugs Show Promise 7:30 a.m. June 2, 2014 - The Wall Street Journal Interactive Edition
Drug Firms Target Smaller Deals 7:21 a.m. June 2, 2014 - The Wall Street Journal Interactive Edition
ASCO '14: Sell-Side Buzz Over Big Pharma Immuno-Oncology Pipelines 6:54 a.m. June 2, 2014 - TheStreet.com
Phase 3 Study Evaluating Yervoy® (Ipilimumab) for Melanoma in an Adjuvant Setting Meets Primary Endpoint of Recurrence-Free Survival 6:38 a.m. June 2, 2014 - benzinga.com
What Merck, Bristol-Myers Squibb And Roche Are Doing To Win The Immuno-Oncology Drugs Market 4:30 p.m. May 30, 2014 - Seeking Alpha
ASCO '14: What's on Tap for Saturday 2:01 p.m. May 30, 2014 - TheStreet.com
Nordic Capital Bidding for Cinven's Sebia 10:25 a.m. May 29, 2014 - The Wall Street Journal Interactive Edition

Thought Leader Opinion Indicates That There is Significant Commercial Opportunity in Developing Therapies that Can Improve Overall Survival in First-Line Advanced Ovarian Cancer 1:00 p.m. June 5, 2014 - PR Newswire - PRF
Bristol-Myers Squibb to Take Part in Goldman Sachs 35th Annual Global Health Care Conference 12:34 p.m. June 3, 2014 - BusinessWire - BZX
Bristol-Myers Squibb and Syngene International Extend Research Collaboration 7:01 a.m. June 3, 2014 - BusinessWire - BZX
Breakthrough Innovation for Animal Health, Upcoming Conference Presentations, and New Treatment Options for Patients - Analyst Notes on Merck, Actavis, Celgene, Bristol-Myers Squibb and GSK 5:50 a.m. May 29, 2014 - PR Newswire - PRF
Premier Biomedical Advances New Cancer Treatment Methodology Protocol 9:01 a.m. May 28, 2014 - ACCESSWIRE
Actavis Confirms Generic Onglyza® Patent Challenge 4:05 p.m. May 27, 2014 - PR Newswire - PRF
Glivec is the Favored First-Line Tyrosine Kinase Inhibitor for Chronic Phase Chronic Myelogenous Leukemia, According to Surveyed European Hematological Oncologists 11:00 a.m. May 27, 2014 - PR Newswire - PRF
Bristol-Myers Squibb and Incyte Enter Clinical Collaboration Agreement to Evaluate Combination Regimen of Two Novel Immunotherapies 7:01 a.m. May 27, 2014 - BusinessWire - BZX
Bristol-Myers Squibb and CytomX Therapeutics Announce Worldwide Collaboration to Develop Probody™ Therapeutics Against Multiple Immuno-Oncology Targets 7:01 a.m. May 27, 2014 - BusinessWire - BZX
Bristol-Myers Squibb and Incyte Enter Clinical Collaboration Agreement to Evaluate Combination Regimen of Two Novel Immunotherapies 7:00 a.m. May 27, 2014 - BusinessWire - BZX
Hepatitis C Therapeutics in Major Developed Markets to 2019 - Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape 12:38 p.m. May 22, 2014 - PR Newswire - PRF
Study Results, Extension of Supply Agreements, Drug Designations, Senior Level Appointments, and Upcoming Events - Analyst Notes on InterMune, Actavis, Bristol-Myers, AbbVie and Illumina 8:30 a.m. May 22, 2014 - PR Newswire - PRF
Basal Cell Carcinoma (Basal Cell Epithelioma) Global Clinical Trials Review, H1, 2014 11:35 a.m. May 21, 2014 - PR Newswire - PRF
Active Stocks Roundup -- Research on Masco Corp., Hecla Mining, Banco Santander, and Bristol-Myers Squibb 11:29 a.m. May 21, 2014 - PR Newswire - PRF
Recognitions, Agreements, Study Results, Data Presentations, and Financial Results - Analyst Notes on Baxter, Incyte, Isis, Celldex Therapeutics, Inc. and Agilent 7:50 a.m. May 19, 2014 - PR Newswire - PRF
TogoRun Named "International Agency Of The Year" At The 2014 PRWeek Global Awards 2:43 p.m. May 16, 2014 - PR Newswire - PRF
Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ASCO Highlights 8:00 a.m. May 16, 2014 - BusinessWire - BZX
Exosomes Common Link in Cancer Drug Development 2:18 p.m. May 15, 2014 - ACCESSWIRE
Exosomes Part and Parcel of Celldex, Pfizer, Incyte and More Cancer Targets 3:50 p.m. May 14, 2014 - ACCESSWIRE
Bristol-Myers Squibb and Celldex Therapeutics Announce Clinical Trial Collaboration to Evaluate the Combination of Investigational Immunotherapies Nivolumab and Varlilumab 8:00 a.m. May 14, 2014 - BusinessWire - BZX

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Novo's Research Unlocks New Insights into Food Noise

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

CARsgen's CAR-T Breakthrough on China's Insurance List

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

IEHP's Wellness Center Launch Faces Delay in California

Unexpected Delay for IEHP's Community Hub Straight outta Rancho Cucamonga, we've got some news that'll have folks in San Bernardino holding their breath a little longer. The Inland Empire Health Plan (or IEHP if you're part of the 1.4 million served by them) had folks pumped for their new Community Wellness Center. But guess what? They had to slam the brakes on the grand...

Advanta's Game-Changer: Acquiring Misr Hytech to Expand in Africa

Advanta's Strategic Move into Africa Alright, let's cut to the chase. Advanta is making a big splash with its acquisition of Misr Hytech, a move that's going to shake things up in Africa's agricultural sector. This isn't just another merger to gloss over with your morning coffee. We're talking about a deal that's supposed to wrap up by January 31, 2027, bringing together...

SmallRig Boosts Art-Driven Innovation in AI Era

The Interplay of Art and AI In a world where the lines between man and machine blur faster than ever, creators like SmallRig are boldly asking: what role should authenticity play when AI takes the stage? The Shenzhen International Art Museum and SmallRig stood shoulder to shoulder, tackling this head-scrambling question with a global gathering of art and tech giants. It's...

Beko Pushes for Policy Synergy Amidst Carbon Shakeup

When big names like Beko step up on the global stage, you pay attention. During the COP31 panels in Antalya, Türkiye, the company's brass made one thing clear: we need harmony in how climate, trade, and finance policies come together. The stakes? The very strength of industrial competitiveness as new carbon rules turn the heat up on manufacturing practices. The Call for...

Windward Bio Surges 68% in Nasdaq Debut

By Ryan Hughes Updated Nov 13, 2026 Category News Views 243

Windward Bio's Impressive Nasdaq Debut Well, how's that for a debut? Windward Bio, this buzzing clinical-stage biotechnology firm, hit Nasdaq like a storm on November 13, 2026. They priced their IPO at $17.00 per share, but by market close, the stock sat comfortably at $28.50. That's a hearty 68% jump on day one, putting their market value at a sweet $1.69 billion. Behind...

Webull Faces Class Action: Key Details for Investors

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

LaserAway Expands to 244 Clinics Over 20 Years

A Milestone in Aesthetic Dermatology Twenty years, folks. That's a long haul for most businesses, let alone one in the fickle field of aesthetic dermatology. LaserAway, the juggernaut in this arena, has just opened its 244th clinic at 6300 Kingery Hwy in Willowbrook, IL. Nothing to be sneezed at. Imagine running a business, let alone one that's been amping up aesthetic...

Greenberg Traurig's Brad Kaufman: A Mentor of Resolute Impact

A Milestone for Mentorship at Greenberg Traurig In the often cutthroat jungle of law, finding someone who actually gives a damn about you is as rare as finding a unicorn. Yet, there it is—Brad Kaufman, at the helm of Greenberg Traurig's professional development, proving that mentorship can be more than just a checkbox on a quarterly review. Award for Exceptional...